Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$0.84 +1.0%	$0.82	$0.70 ▼ $1.65	$64.30M	2.05	360,985 shs	61,693 shs
CRDF Cardiff Oncology	$4.42 +7.3%	$3.40	$2.01 ▼ $5.64	$274.09M	1.52	1.22 million shs	1.92 million shs
FENC Adherex Technologies	$8.92 +2.4%	$7.99	$3.96 ▼ $9.30	$240.40M	0.39	92,327 shs	48,846 shs
IMMP Prima BioMed	$1.64 +0.6%	$1.78	$1.32 ▼ $2.72	$238.04M	1.71	158,764 shs	73,418 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	-0.19%	-0.65%	+3.43%	-4.87%	-33.27%
CRDF Cardiff Oncology	-0.24%	+4.57%	+8.14%	+46.62%	+64.14%
FENC Adherex Technologies	-0.91%	+0.11%	+9.84%	+70.78%	+33.18%
IMMP Prima BioMed	-3.55%	-4.12%	-6.32%	+12.41%	-20.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.0587 of 5 stars	3.5	3.0	3.3	0.0	0.0
CRDF Cardiff Oncology	1.2273 of 5 stars	3.4	0.0	2.0	0.0	0.6
FENC Adherex Technologies	2.4611 of 5 stars	3.6	1.0	2.9	3.3	0.0
IMMP Prima BioMed	1.5053 of 5 stars	3.5	1.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	3.00	Buy	$4.75	468.18% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$11.70	164.71% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	45.74% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside

Current Analyst Ratings Breakdown

Latest CLSD, IMMP, CRDF, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$1.66M	39.14	N/A	N/A	($0.51) per share	-1.64
CRDF Cardiff Oncology	$680K	432.45	N/A	N/A	$1.86 per share	2.38
FENC Adherex Technologies	$47.54M	5.18	$0.03 per share	269.69	($0.21) per share	-42.48
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)

Latest CLSD, IMMP, CRDF, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	3.19	3.19
CRDF Cardiff Oncology	N/A	6.22	6.22
FENC Adherex Technologies	N/A	5.13	4.97
IMMP Prima BioMed	N/A	18.86	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
CRDF Cardiff Oncology	16.29%
FENC Adherex Technologies	55.51%
IMMP Prima BioMed	2.32%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	6.20%
CRDF Cardiff Oncology	7.70%
FENC Adherex Technologies	11.76%
IMMP Prima BioMed	3.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.35 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable

CLSD, IMMP, CRDF, and FENC Headlines

Recent News About These Companies

Immutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma Trial

May 28, 2025 | tipranks.com

Immutep Limited: Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025 | finanznachrichten.de

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025 | globenewswire.com

Immutep’s efti combination meets primary endpoint in Phase II soft tissue sarcoma trial

May 26, 2025 | sharecafe.com.auS

Immutep’s Efti Combination Therapy Achieves Success in Phase II Soft Tissue Sarcoma Trial

May 25, 2025 | tipranks.com

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 16, 2025 | manilatimes.netM

Immutep reports promising lung cancer trial results

May 16, 2025 | investing.com

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

May 15, 2025 | finance.yahoo.com

Is Immutep Limited (IMMP) the Best Australian Stock to Buy According to Analysts?

May 15, 2025 | msn.com

Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial

May 14, 2025 | tipranks.com

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025 | seekingalpha.com

Immutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS

May 5, 2025 | manilatimes.netM

Immutep’s Efti Shows Promising Results in Head and Neck Cancer Trial

May 4, 2025 | tipranks.com

Immutep Quarterly Activities Report Q3 FY25

April 29, 2025 | finance.yahoo.com

Immutep Limited Reports First Patient Dosed in TACTI-004 Phase III Lung Cancer Trial and Updates on Clinical Progress

April 29, 2025 | quiverquant.comQ

Immutep Advances Cancer Trials with Promising Developments

April 28, 2025 | tipranks.com

Immutep to Participate in Upcoming Investor Conferences

April 2, 2025 | globenewswire.com

Immutep to Engage in Key Investor Conferences

April 1, 2025 | tipranks.com

Immutep: A Small Company With A Pipeline Resembling Big Pharma

March 31, 2025 | seekingalpha.com

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

March 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, IMMP, CRDF, and FENC Company Descriptions

Clearside Biomedical NASDAQ:CLSD

$0.84 +0.01 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.86 +0.02 (+2.63%)

As of 07:50 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Cardiff Oncology NASDAQ:CRDF

$4.42 +0.30 (+7.28%)

Closing price 04:00 PM Eastern

Extended Trading

$4.46 +0.04 (+0.90%)

As of 07:42 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Adherex Technologies NASDAQ:FENC

$8.92 +0.21 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$8.92 0.00 (0.00%)

As of 04:04 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.65 +0.01 (+0.55%)

As of 07:28 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time